

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: PENN-0798
Inventors: Clevenger and Ryczyn
Serial No.: Not Yet Assigned
Filing Date: Herewith
Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Title: Methods and Compositions for Modulating Somatolactogenic Functions

I, **Jane Massey Licata**, Registration No. 32,257, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date: February 14, 2002

Jane Massey Licata
Jane Massey Licata, Registration No. 32,257

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into

the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i) (1).

(**XX**) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously

submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: February 14, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Sheet 01 of 02

Form PTO-1449 Modified

Docket No.
PENN-0798Serial No.
Not Yet AssignedList of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)Applicant
Clevenger and RyczynU.S. Department of Commerce
Patent and Trademark OfficeFiling Date
HerewithGroup
Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner		Document	Date	Name	Class	Subclass
	AA	5,523,227	6-4-96	Bram et al.	435	240.2

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	

EXAMINER

DATE CONSIDERED

Sheet 02 of 02

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. PENN-0798	Serial No. Not Yet Assigned
		Applicant Clevenger and Ryczyn	
		Filing Date Herewith	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Allain et al., "Characterization of Surface Binding Sites for Cyclophilin B on a Human Tumor T-cell Line", <i>J. Biol. Chemistry</i> 1994 269(24):16537-16540	
	AB	Allain et al., "Selective assay for CyPA and CyPB in human blood using highly specific anti-peptide antibodies", <i>J. Immunological Methods</i> 1995 178:113-120	
	AC	Denys et al., "Involvement of two classes of binding sites in the interactions of cyclophilin B with peripheral blood T-lymphocytes", <i>Biochem.</i> 1998 336:689-697	
	AD	Denys et al., "Distribution of cyclophilin B-binding sites in the subsets of human peripheral blood lymphocytes", <i>Immunology</i> 1997 91:609-617	
	AE	Mariller et al., "Involvement of the N-terminal part of cyclophilin B in the interaction with specific Jurkat T-cell binding sites", <i>Biochemical Journal</i> 1996 317:571-576	
	AF	Mertani et al., "Cellular Expression of Growth Hormone and Prolactin Receptors in Human Breast Disorders", <i>Int. J. Cancer Pred. Oncol.</i> 1998 79:202-211	
	AG	Price et al., "Cyclophilin B trafficking through the secretory pathway is altered by binding of cyclosporin A", <i>Proc. Natl. Acad. Sci. USA</i> 1994 91:3931-3935	
	AH	Price et al., "Human cyclophilin B: A second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence", <i>Proc. Natl. Acad. Sci. USA</i> 1991 88:1903-1907	
EXAMINER		DATE CONSIDERED	